

510(k) Summary

DCT 2 9 2010

This summary of 510(K) – safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date: <u>09-02-2010</u>

1. Submission Sponsor

	Submitter
Name	DO Co.,Ltd.
Address	551-1, Yongsan-dong, Yuseong-gu,
	Daejeon, 305-500, South Korea
Phone	Tel: +82-42-935-8926~9
Fax	Fax: +82-42-936-8927

2. Submission Correspondent

LK Consulting Group 2341 W. Crescent Ave. #3, Anaheim, CA 92801 Priscilla Chung

Phone: 714-844-2612 Fax: 714-409-3357

Email: agent.fda@gmail.com

3. Device

Trade Name: Ortho MTA(Mineral Trioxide Aggregate)

• Common Name: Root filling material

Classification Name: Root canal filling resin
 Classification regulation: 21 CFR 872.3820

Product Code: KIF

4. Predicate Device

White MTA Material (K011009), Dentsply International

5. Description:

Ortho MTA (Mineral Trioxide Aggregate) is ideal for orthograde root canal filling. Ortho MTA (Mineral Trioxide Aggregate) is compositionally formulated to have the physical properties, setting requirements and characteristics necessary for a clinically effective root canal filling material.

6. Indications for use:

- · Orthograde root canal filling material
- Repair of root perforations during root canal therapy (endodontic therapy), or as a consequence of internal resorption
- Repair of root canals as an apical plug during apexification
- · Root end filling
- Pulp capping

7. Safety and Effectiveness:

Ortho MTA(Mineral Trioxide Aggregate) has similar physical and biocompatible properties, and demonstrates comparable performance specifications to White MTA Material(Predicate device). In addition, Ortho MTA (Mineral Trioxide Aggregate) has a comparable delivery system to White MTA Material.

The bench and biocompatibility testing performed demonstrates that any differences in their technological characteristics do not raise any new questions as to safety and effectiveness. Therefore, it is concluded that Ortho MTA (Mineral Trioxide Aggregate) is safe, effective and substantially equivalent to the predicate device.

8. Conclusion

Based on the information provided in this premarket notification, Ortho MTA (Mineral Trioxide Aggregate) is safe, effective and substantially equivalent to the predicate devices as described herein.







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room ~WO66-G609 Silver Spring, MD 20993-0002

DO Company, Limited C/O Ms. Priscilla Chung LK Consulting Group 2341 West Crescent Avenue, #3 Anaheim, California 92801

UCT 2 9 2010

Re: K102575

Trade/Device Name: Ortho MTA (Mineral Trioxide Aggregate)

Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin

Regulatory Class: II Product Code: KIF

Dated: September 8, 2010 Received: September 8, 2010

Dear Ms. Chung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801). please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):	K102575	OCT 2 9 2010
Device Name: Ortho MTA (Mine	eral Trioxide Aggregate)	
Indications For Use:	,	
Orthograde root canal filling m	naterial	
• Repair of root perforations duri of internal resorption	ing root canal therapy(endodon	tic therapy), or as a consequence
• Repair of root canals as an apic	cal plug during apexification	
• Root end filling		
• Pulp capping		
Prescription Use√_ (Per 21 CFR 801 Subpart D)	AND	Over-The Counter Use(21 CFR 807 Subpart C)
(Per 21 CFR 801 Subpart D)		
(Per 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BE		(21 CFR 807 Subpart C)
(Per 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BE DED)	of CDRH, Office of Device Ex	(21 CFR 807 Subpart C) E ON ANOTHER PAGE IF NEE Faluation (ODE) hasiology, General Hospital
(Per 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BE DED)	of CDRH, Office of Device Experience of Anesti	(21 CFR 807 Subpart C) E ON ANOTHER PAGE IF NEE Faluation (ODE) hasiology, General Hospital